A practical approach for the assessment of bioequivalence under selected higher-order cross-over designs

Statistics in Medicine

Volumn 16, Issue 19, 1997, Pages 2229-2243

  Vuorinen, Jouni ^a  

^a ORION CORPORATION   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOEQUIVALENCE; CROSSOVER PROCEDURE; DRUG COMPARISON; METHODOLOGY; STATISTICS;

AMINOSALICYLIC ACIDS; COLITIS, ULCERATIVE; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; HUMANS; MODELS, STATISTICAL; REFERENCE VALUES; THERAPEUTIC EQUIVALENCY;

EID: 0030884090     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0258(19971015)16:19<2229::AID-SIM643>3.0.CO;2-S     Document Type: Article

References (40)

1. Grizzle, J. E. 'The two-period changeover design and its use in clinical trials', Biometrics, 21, 467-480 (1965).
2. Grieve, A. P. 'The two-period changeover design in clinical trials', Letter to the editor, Biometrics, 38, 518 (1982).
3. Chow, S. C. and Liu, J. P. 'On assessment of bioequivalence under a higher-order crossover design', Journal of Biopharmaceutical Statistics, 2, 239-256 (1992).
4. Locke, C. S. 'An exact confidence interval from untransformed data for decision-making in bioequivalence assessment', Journal of Pharmacokinetics and Biopharmaceutics, 12, 649-655 (1984).
5. Yee, K. F. 'The calculation of probabilities in rejecting bioequivalence', Biometrics, 42, 961-965 (1986).
6. Vuorinen, J. and Tuominen, J. 'Fieller's confidence intervals for the ratio of two means in the assessment of average bioequivalence from crossover data', Statistics in Medicine, 13, 2531-2545 (1994).
7. Locke, C. S. 'Use of a more general model for bioavailability studies', Communications in Statistics - Theory and Methods, 19, 3361-3373 (1990).
8. Anderson, S. and Hauck, W. W. 'Consideration of individual bioequivalence', Journal of Pharmacokinetics and Biopharmaceutics, 18, 259-273 (1990).
9. Hauck, W. W. and Anderson, S. 'Individual vs. average bioequivalence: when is average not sufficient?', Proceedings of the Bio-International '94, 87-90 (1994).
10. Schall, R. 'A unified view of individual, population and average bioequivalence', Proceedings of the Bio-International '94, 91-106 (1994).
11. Chow, S. C. and Liu, J. P. 'Current issues in bioequivalence trials', Drug Information Journal, 29, 795-804 (1995).
12. Steinijans, V. W., Hauschke, D. and Schall, R. 'International harmonization of regulatory requirements for average bioequivalence and current issues in individual bioequivalence', Drug Information Journal, 29, 1055-1062 (1995).
13. Chow, S. C. and Liu, J. P. Design and Analysis of Bioavailability and Bioequivalence Studies, Marcel Dekker, New York, 1992.
14. Jones, B. and Kenward, M. G. Design and Analysis of Cross-over Trials, Chapman and Hall, London, 1989.
15. Ryde, M., Huitfeldt, B. and Pettersson, R. 'Relative bioavailability of Olsalazine from tablets and capsules: a drug targeted for local effect in colon', Biopharmaceutics & Drug Disposition, 12, 233-246 (1991).
16. Schuirmann, D. J. 'A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability', Journal of Pharmacokinetics and Biopharmaceutics, 15, 657-680 (1987).
17. Schuirmann, D. J. 'Confidence intervals for the ratio of two means from a crossover study', Proceedings of the Biopharmaceutical Section of the American Statistical Association, 121-126 (1989).
18. Liu, J. P. and Weng, C. S. 'Estimation of direct formulation effect under log-normal distribution in bioavailability/bioequivalence studies', Statistics in Medicine, 11, 881-896 (1992).
19. Liu, J. P. and Weng, C. S. 'Evaluation of log-transformation in assessing bioequivalence', Communications in Statistics - Theory and Methods, 23, 421-434 (1994).
20. Liu, J. P. and Chow, S. C. 'On the assessment of variability in bioavailability/bioequivalence studies', Communications in Statistics - Theory and Methods, 21, 2591-2607 (1992).
21. Chinchilli, V. M. and Esinhart, J. D. 'Design and analysis of intra-subject variability in cross-over experiments', Statistics in Medicine, 15, 1619-1634 (1996).
22. Scheffé, H. The Analysis of Variance, Wiley, New York, 1959.
23. Graybill, F. A. An Introduction to Linear Statistical Models, McGraw-Hill, New York, 1961.
24. Searle, S. R., Casella, G. and McCulloch, C. E. Variance Components, Wiley, New York, 1992.
25. Guilbaud, O. 'Exact comparisons of means and within-subject variances in 2 x 2 crossover trials', Drug Information Journal, 29, 857-870 (1995).
26. Dighe, S. V. and Adams, P. 'Bioequivalence: A United States regulatory perspective', in Welling, P. G., Tse, F. L. S. and Dighe, S. V. (eds), Pharmaceutical Bioequivalence, Marcel Dekker, New York, 1991.
27. Patterson, H. D. and Thompson, R. 'Recovery of inter-block information when block sizes are unequal', Biometrika, 58, 545-554 (1971).
28. Searle, S. R. Linear Models, Wiley, New York, 1971.
29. Patterson, H. D. and Thompson, R. 'Maximum likelihood estimation of components of variance', Proceedings of the 8th International Biometric Conference, 197-207 (1975).
30. Jennrich, R. I. and Schluchter, M. D. 'Unbalanced repeated-measures models with structured covariance matrices', Biometrics, 42, 805-820 (1986).
31. Brown, H. K. and Kempton, R. A. 'The application of REML in clinical trials', Statistics in Medicine, 13, 1601-1617 (1994).
32. SAS Technical Report P-229, SAS Institute Inc., Cary. 'SAS/STAT software: changes and enhancements', 287-366 (1992).
33. Wolfinger, R. 'A tutorial on mixed models', SAS Institute Inc., Cary, 1992.
34. Hwang, S., Huber, P. B., Hesney, M. and Kwan, K. C. 'Bioequivalence and interchangeability', Journal of Pharmaceutical Science, 67, IV (1978).
35. The Division of Bioequivalence, Office of Generic Drugs, US Food and Drug Administration. 'Statistical procedures for bioequivalence studies using a standard two-treatment crossover design', 1992.
36. Commission of the European Communities, CPMP working party on efficacy of medicinal products. 'Investigation of bioavailability and bioequivalence', 1991.
37. Anderson, S. 'Current issues of individual bioequivalence', Drug Information Journal, 29, 961-964 (1995).
38. Schall, R. and Luus, R. E. 'On population and individual bioequivalence', Statistics in Medicine, 12, 1109-1124 (1993).
39. Sheiner, L. B. 'Bioequivalence revisited', Statistics in Medicine, 11, 1777-1788 (1992).
40. Endrenyi, L. 'A simple approach for the evaluation of individual bioequivalence', Drug Information Journal, 29, 847-855 (1995).